Linvoseltamab-gcpt
Details of the Drug
- Generic Name:
- Linvoseltamab-gcpt
- Drug Type:
- Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager
- How the Drug is Given:
Injection, for intravenous use
- Names:
- Lynozyfic™
- Linvoseltamab-gcpt
Indications and Usage
Linvoseltamab-gcpt is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Side effects needing medical attention
The most common adverse reactions are musculoskeletal pain, cytokine release syndrome (CRS), cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and shortness of breath. The most common laboratory abnormalities are decreased lymphocyte count, decreased neutrophil count, decreased hemoglobin, and decreased white blood cell count.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.